Many cannabis stocks have been trading in the red this week after the Food and Drug Administration issued health warnings.

The FDA has issued a scary new list of health warnings to consumers on Monday, warning that the cannabis ingredient CBD can cause liver damage, “changes in mood,” and “gastrointestinal distress,” among other ailments.

“The FDA is concerned that people may mistakenly believe that trying CBD “can’t hurt,” the consumer alert read.

This is the first warning from the FDA ever about the potential health risks of CBD-infused products.

“It’s the most stern aggressive language to date,” remarked Jonathan Eppers, chief executive of LA-based Vybes whose CBD-infused drinks are sold in 3,000 stores.

Shares of Aurora Cannabis were down 5%, Cronos Group was down 2.3% while Tilray and Canopy Growth were down 3.5% and 1.8% respectively.

“It laid out potential adverse health effects, but they haven’t said for sure whether CBD is safe or not safe. It’s still a state of uncertainty,” Eppers said. “It feels like they are continuing to punt this down the road.”

Principal Deputy Commissioner of Food and Drugs Dr. Amy Abernethy tweeted, “Often, people wrongly think that the myriad of CBD products on the market have been evaluated by FDA and determined to be safe, or that trying CBD can’t hurt. Aside from one prescription drug, CBD products have not been approved by FDA.”

She also wrote, “There are number of questions regarding CBD’s safety and there are real risks that need to be considered. There is significant interest in CBD and we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products.”


Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

College Students Holiday Gift Guide
08 December 2021
Millennials in California Want Marijuana Over Alcohol
15 June 2017
New York’s First Woman-Owned Dispensary Opens Tomorrow
29 March 2023